Information  X 
Enter a valid email address

Feedback PLC (FDBK)

  Print          Annual reports

Thursday 10 June, 2021

Feedback PLC

Bleepa available on Apple App Store & Google Play

RNS Number : 3812B
Feedback PLC
10 June 2021

Reach announcement


Feedback plc


Bleepa now available on Apple App Store and Google Play


· Available for download under 'Bleepa' app name

· App available for all devices including Apple technologies and android devices

· An essential app for remote, secure communications between clinicians and teams at the touch of a button


London, 10 June 2021: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, today announces that Bleepa, Feedback's flagship medical imaging communications platform, has completed a comprehensive evaluation and is now available for clinicians to download on all devices through the Apple App Store and Google Play. For hospitals with a Bleepa contract, clinical users will now be able to simply download the app and easily access Bleepa through a registered login process. Access through the Apple App Store and Google Play will make it easier to roll out Bleepa at customer sites as clinicians will now be able to download the app directly to their own devices.


Bleepa is an essential tool for remote, secure communications between clinicians and teams - an easy-to-use, digital medical imaging communications platform that enables clinicians to safely view and discuss imaging and patient cases at the touch of a button. 


· Bleepa is a CE marked medical device and is the only regulated platform on the NHSx Clinical Communications Framework that enables users to share images such as X-ray, CT, MRI or ultrasound at a standard approved for clinical use. 

· Equipping frontline teams with the ability to see patient imaging, alongside instant-messaging-based case discussion and video calls can support them to make more informed decisions faster, enabling better, safer patient care.

· Offers latest features including the Photocapture module which enables clinicians to acquire clinical images of patients, such as in-field medical photographs of skin lesions or wounds; and Document Capture to encapsulate additional patient information, ECG and blood test results within the patient record from which to share discuss with colleagues.

· With medical imaging forming the basis of almost all clinical decision-making processes, flexible access on the go has never been more essential for a rapidly evolving workforce.

· Bleepa can facilitate clinical referrals and treatment decisions within a hospital, between hospitals and pan-regionally offering truly networked care.

· As Bleepa can be accessed from any internet-connected device, it is possible to maintain control of patient cases even when working remotely. It is easy to create a secure network with all the information and functionality needed for clinicians to manage workloads more effectively.

· From the moment patients are registered, Bleepa can enable smoother and swifter transfer from one medical team to another, from referral to decision, treatment and exit.


Dr Tom Oakley, CEO of Feedback, commented:


"We are passionate about improving the lives of those on our medical frontline, particularly in these COVID-19 times.  Bleepa is revolutionising the way in which clinicians communicate by enabling clinicians to maintain control even when working remotely, smooth the patient experience and create a more effective and cohesive working environment. Bleepa is most effective when used on an individual's mobile device and our successful approval for both the Apple App Store and Google Play is a key step in accelerating user rollout at customer sites. Let's put quality images back where they belong - in the hands of the frontline - not tomorrow, but right now, today."



Feedback plc

Tom Oakley, CEO


Feedback media:

Nick Mayhew, Chief Marketing Lead

+44 (0)1954 718072

[email protected]



+44 (0) 7736 065353



Allenby Capital Limited (Nominated Adviser)

David Worlidge / Vivek Bhardwaj

+44 (0)20 3328 5656



Peterhouse Capital Limited (Joint Broker)

Lucy Williams / Duncan Vasey

+44 (0)20 7469 0936



Stanford Capital Partners Limited (Joint Broker)

Patrick Claridge / John Howes

+44 20 3815 8880



Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected]

Paul McManus/Nick Rome/Nicholas Johnson

07980 541 893 or 07748 325 236 or 07884 664 686



Notes to Editors


Feedback plc (AIM: FDBK) is a medical imaging technology business. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go. 


Its highly scalable Software as a Service ("SaaS")-based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care facilitators. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of diagnosis.


About Reach announcements


This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.


This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t